EarningsQ2 2026 Earnings Report
DE:5MO Q2 2026 EPS Results
Actual EPS€0.04
Consensus EPS€0.08
Beat/MissMissed by -€0.05
One Year Ago EPS€0.37
DE:5MO Q2 2026 Revenue Results
Actual Revenue€166.20M
Expected Revenue€178.40M
Beat/MissMissed by -€12.21M
YoY Revenue Growth-20.42%
Earnings Announcement Details
QuarterQ2 2026
Date08/05/2026
TimeAfter Close
Conference CallWednesday, August 5, 2026
DE:5MO Upcoming Earnings
Onterris's next earnings date is estimated for November 10, 2026, based on past reporting schedules.
Q2 2026 Earnings Call Audio
DE:5MO Q2 2026 Earnings Call
0:00 / 0:00
Q2 2026 Earnings Slide Deck
Q2 2026 Earnings Call Summary
Earnings Call Sentiment|Neutral
The call presented a mixed picture: revenue and segment topline performance were weaker than prior year due to an unusually low emergency response environment and lower pass‑through revenue, and first‑half operating cash flow was negative. Offsetting these headwinds, management highlighted durable margin expansion, successful cost optimization, a record‑setting adjusted EBITDA outlook, a strong H2 cash flow plan, visible project backlog in testing and Consulting & Treatment, and continued disciplined capital allocation (share repurchases and planned bolt‑on M&A). Given the substantial operational improvements and cash‑flow guidance that counterbalance meaningful revenue shortfalls and near‑term uncertainty from a Board strategic review, the tone of the call is cautious but constructive.Company Guidance
Improved Profitability and Record EBITDA Guidance
Consolidated adjusted EBITDA was $31.9 million in Q2 with an EBITDA margin of 17.1% (up from 16.9% in prior-year quarter). Updated full‑year adjusted EBITDA guidance of $117 million to $120 million; company noted every outcome in this range would represent a new record. At the midpoint, management expects ~150 basis points of margin expansion versus last year and ~50 basis points of improvement versus original 2026 guidance.
Successful Cost Optimization and Operating Efficiency
Management attributes margin improvement to ongoing cost optimization and operating efficiencies that offset a notable portion of lower revenue; the company quantified a net $5.5 million benefit to EBITDA from 'other impacts' (cost optimization and operating efficiency) in the guidance bridge.
Strong Cash Flow Outlook and Capital Allocation
Company expects $70 million to $80 million of operating cash flow in the second half of 2026 and targets operating cash conversion of approximately 60% of full‑year EBITDA. Despite year‑to‑date activity (1.6M shares repurchased for $30M and $10.8M contingent consideration paid), management expects year‑end leverage of ~2.5x and reported total available liquidity of $160.8 million at June 30.
Consulting & Treatment Segment Margin Improvement
Consulting and Treatment adjusted EBITDA margin improved to 22.2% in Q2 from 21.9% a year earlier, reflecting favorable project mix and improved operating performance despite a lower revenue base.
Predictable Testing Business and Visible Backlog
Management emphasized strong underlying demand in the testing business and known Consulting & Treatment projects as the basis for confidence in back‑half performance; provided Q3 revenue expectations of $190 million to $210 million with an expected EBITDA margin of 17% to 18% at the midpoint.
DE:5MO Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed